ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total value of $455,420.00. Following the completion of the sale, the director now owns 75,218 shares in the company, valued at approximately $17,127,890.78. This represents a 2.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
ResMed Stock Performance
Shares of NYSE RMD opened at $225.08 on Friday. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The stock has a 50 day simple moving average of $236.72 and a 200-day simple moving average of $239.80. The company has a market cap of $33.06 billion, a PE ratio of 26.57, a P/E/G ratio of 1.53 and a beta of 0.70. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05.
ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, equities research analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.
ResMed Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.94%. ResMed's dividend payout ratio is currently 25.03%.
Institutional Trading of ResMed
Large investors have recently added to or reduced their stakes in the company. True Wealth Design LLC raised its stake in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 110 shares during the period. Colonial Trust Co SC boosted its holdings in ResMed by 6,250.0% in the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 125 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in ResMed in the third quarter worth $34,000. Optiver Holding B.V. bought a new stake in ResMed in the fourth quarter worth $33,000. Finally, Itau Unibanco Holding S.A. boosted its holdings in ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 150 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on ResMed in a research note on Thursday, January 16th. They set a "buy" rating on the stock. Stifel Nicolaus reduced their price target on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. increased their target price on ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. KeyCorp increased their target price on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $243.82.
Check Out Our Latest Research Report on RMD
About ResMed
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
